Loading clinical trials...

Thalamus Seizure Detection With a Deep Brain Stimulator System | Clinical Trials | Clareo Health

RECRUITINGNA

Thalamus Seizure Detection With a Deep Brain Stimulator System

Seizure Detection With a Deep Brain Stimulation System

NCT06700356•Mayo Clinic

Summary

The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age and older.
•Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).
•Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria

•Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.
•Women will verify not pregnant, and if applicable, have urine pregnancy test.
•Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
•Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

June 1, 2026

Primary Completion Date

November 1, 2026

Completion Date

May 1, 2027

Last Updated

March 20, 2026

Enrollment

ESTIMATED participants

Conditions

Epilepsy; Seizure

Interventions

Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring

DEVICE

Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient

DEVICE

Contacts

Karla Crockett

CONTACT

507-538-4880 crockett.karla@mayo.edu

Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

NCT06278428

Epilepsy; SeizureChild Development+2 more

View study

COMPLETED

Earbud EEG Feasibility Study

NCT05257811

Epilepsy; SeizureSleep

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Thalamus Seizure Detection With a Deep Brain Stimulator System

Inclusion Criteria

Exclusion Criteria

Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

Earbud EEG Feasibility Study

ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

ZEBinix® Retention Rate in Epilepsy in Elderly Patients